8.590 9.77%

Research Hotspot

Click Each Keyword to Figure Out More

Epithelial Use Cisplatin Anticancer Prognosis Blood Note Syndrome Sensitizes Ultrasound Induction Node Expansion Invasive Exhibit Car Cutaneous Improve Lymph Screening Amg First-in-human Resection Can Pharmacodynamic Negative Phenotype Confers Doe Regulator Transcriptomic Paclitaxel Bone Woman Index Metabolism Ib Natural Design Ib/ii Precursor Benefit Change Oncolytic Colon Small-cell Aurora Biopsy Alpha Temozolomide Innate Metformin High Dose-escalation Cll Fibrosis System Antibody-drug Comparison Parp Induces Cohort Significance Hodgkin Residual Comprehensive Single-cell Group Next-generation Future Control Learning Proliferation Diagnostic Hpv Cell-free Cetuximab High-grade Tissue Grade Hope Microsatellite Window Locally Cellular Functional Dual Ibrutinib Tumor-infiltrating Candidate Follicular Angiogenesis Increase Panel Escalation Pi3k Her2 B Bromodomain Poor Intrahepatic Infiltrate Induced Sample Variant Urothelial Homologous Platinum Disseminated Pet Serum Predicting First-in-class Bispecific Synthetic Induce Targetable Ligand Report Enhanced Tomography Deep Mismatch Activating Uveal Profile Antagonist Ezh2 Subset Tp53 Apoptosis Subtyping Vedotin Neoplasm Damage Translational Interaction Aml Sunitinib Highly Rate Carboplatin Intratumoral Utility Systemic Release Ipilimumab Oncogenic Translation Surface Extracellular Trigger Enhance Modulation Administration Directly Deficiency Rituximab Pattern Longitudinal Trastuzumab Abiraterone Lymphocytic Suppression Across Clear Merkel Vulnerability Score Beyond Genetic Kras Gynecologic Characteristic Esophageal Aggressive Palbociclib Carcinogenesis Classifier Prevents Acetate Recombination Prevent Radioresistance Anti-egfr Relevant Exon Central Liquid Everolimus Synergize Hpv-associated Skin Mogamulizumab Biological Il15 Autocrine Endocrine Membrane Cholangiocarcinoma Etoposide Imatinib Radioimmunotherapy Optimized Independent Nsclc Osimertinib D Loop Nomogram Patient-derived Matched Compared Resected Subject Identify Early-phase Value Cycle Program Concurrent Option Doxorubicin Mapk Anaplastic Foxp3 Ewing Germline Radiosensitization Monotherapy Rb1 Fgfr Condition Mutational Neutrophil Margin Manner Multicentric Anti-gd2 Alk Marrow Instability Histone Mitochondrial Number Fact Cluster Exercise Acid Radiomics Alone Previously Hcc Potentially Injection Aberration Single Bet Host Potentiates Capecitabine At-risk Macroglobulinemia Pharmacokinetics Trabectedin Positron Gastroesophageal Improved Synergistic Adoptive Abscopal Early-stage Il6 Discovery Transition Vesicle Osteosarcoma Transplantation Nab-paclitaxel Difference Suppressor Bortezomib Silencing Akt Hsp90 Hdac Resonance Individual Experimental Esophagogastric Activated Magnetic Amplification Infection Liver Quantitative Diagnosis Nervous Prior Complete Nrg1 Surrogate Origin Myelodysplastic Dendritic State Prodrug Sorafenib Acquired Chemoradiation Intrinsic Regulation Tolerability Deplete Validated Transcriptional Double-blind Classification Effector Age Ar-v567es Myelofibrosis Vaccination Liposomal Time Arginine Surveillance Normal Action Cancer-letter Gemcitabine Emission Untreated Medicine Lncrna Differentiated Distinguishing Mutant Radiation-induced Endometrial Selectively Robust Antigen-specific Cooperate Endoscopic Significant Soft-tissue Intracranial Line Vegf-a Defines Rapamycin Gefitinib Finding Chemoresistance Mortality Heel Neratinib Alisertib Their Egfr-tki Yield Dilution Incidence Immunosuppression Degrader Paradigm Opportunity Affect Genotyping Mr Synthesis Testing Viral Ar Right Diversity Hif-2 Influence Space Polymorphism Carcinoma-associated Reduced Debio Test Esr1 Contrast-enhanced Copy Property Distribution Modifies Current Genetics Assay Identified Sodium Concomitant Act Inhibit Long-term Mycosis Vegfr Degradation Cytarabine Promoter Chemoradiotherapy Chemotherapeutic Overcomes Contribute Modulator Bcl-2 Initiate Immuno-pet Mirnas Multiparametric Vitamin Engagement Pazopanib Associate Accuracy Density Treatment-naïve Application Prexasertib Farnesyl Contrast Domain Particle Junction Nonmetastatic Dependent Evolution Block Flt3 Kaposi Integration Mucosal Inhibiting Enhancing Insulin-like Phosphatase Evaluating Guadecitabine Nuclear Predictor Deacetylase Smad7 Data Fibroblast Pharmacokinetic Standard Local Adolescent Post Platinum-resistant Exploitation Cytotoxicity Dopamine Disparity Senescence Image Glasdegib Blood-brain Generation Adaptive Granulosa Braf-mutant Contribution Telomerase Monoclonal Mek Preoperative Spectrum Multi-center Fatty Evasion Flash Crosstalk Dll3 Gd2-specific Carfilzomib Contributing Inform Mesothelioma Mesenchymal Prevention Clonotypic Sex Systhers Medulloblastoma Consensus Tremelimumab Atr Lapatinib Evolutionary Cd19 Microrna Emtansine Leiomyosarcoma Brca1 Fulvestrant Arm Synthase Spatially Review Ercc1 Sentinel Cd4 Pten Effectiveness Cancer-induced No Epidermal Igf1r Selinexor Rapid Salivary Tumorigenesis Nodule Ido Immunologic Glutamine Tkis Dosing Than Stereotactic Anti-cd38 Activator Extraterminal Promise Overexpression Focus Ca19-9 Mirna Peptide Pancreas Antileukemic Vemurafenib Postoperative Panobinostat Volume Enables Calcium High-dose Viability Older Isocitrate Management Event Regimen Go Feedback Rechallenge Igm Ctdna Undergoing Relationship Pharmacologic Regression Demonstrates Dicer1 Mass Cyclophosphamide Somatostatin Active Culture Letrozole Nk Pharmacogenomic Megakaryocyte Regorafenib Il12 Chemosensitivity Fungoides Notch Estrogen Dexamethasone Transgenic Evidence Machine Vascular Genome Surgical Multi-omics Importance Followed Shift Young Forecast Pathologic Chk1 Dabrafenib High-throughput Critical Protumorigenic Gm-csf Vulnerable Provides Secretion Following Vaccinia Tmb Presentation Cancer-response Persistence First Pemetrexed Administered Ionizing Personalized Somatic Resistant Bcg Transcription Pd1 Antagonism Anal Cd19car-t Trametinib Nerve Exclusion Activates Hla Exchange Waldenström Cxcr4 Memory Hepatitis Network Regulates Pegylated From Liposarcoma On-target Meta-analysis Intensive Advantage Smad4 Infusion Course Related Immunomodulation Neoaltto Sheath Hnscc Suppress Prevalence Inverse Organoid Rational Transcriptome Meningioma Distant Gland Adverse Neoplastic Foster Transferase T-all Cabozantinib Docetaxel Allogeneic Stem-like Radiosensitizes Transplant Er Facilitates Cisplatin-induced Barrier Complex Minimally Follow-up Misclassification Low Feature Uterine Near-infrared Remission Body Chemokine End Hypoxia Fluorescence-guided Enteropathy Overcome Serous Depletion Dock4 Retraction Initiation Intermediate-risk Pontine Vorinostat Formation Disruption Radiosensitivity Fluorescence Lead Notch1 Suppresses

Clinical Cancer Research - Journal Impact

The Journal Impact 2019-2020 of Clinical Cancer Research is 8.590, which is just updated in 2020. Compared with historical Journal Impact data, the Factor 2019 of Clinical Cancer Research dropped by 9.77% . The Journal Impact Quartile of Clinical Cancer Research is Q1. The Journal Impact of an academic journal is a scientometric factor that reflects the yearly average number of citations that recent articles published in a given journal received. It is frequently used as a factor for the relative importance of a journal within its field; journals with higher Journal Impact are often deemed to be more important than those with lower ones. The Journal Impact measures the average number of citations received in a particular year (2019) by papers published in the journal during the two preceding years (2017-2018). Note that 2019 Journal Impact are reported in 2020; they cannot be calculated until all of the 2019 publications have been processed by the indexing agency. In addition to the 2-year Journal Impact, the 3-year Journal Impact can provide further insights and factors into the impact of Clinical Cancer Research.

9.5 ~ 10.0


Clinical Cancer Research - Journal Impact Prediction System

50% scientists expect Clinical Cancer Research Journal Impact 2020 will be in the range of 9.5 ~ 10.0. Journal Impact Prediction System provides an open, transparent, and straightforward platform to help academic researchers Predict future factor and performance through the wisdom of crowds. Journal Impact Prediction System displays the exact community-driven factor without secret algorithms, hidden factors, or systematic delay.

Clinical Cancer Research Journal Impact Prediction System - Factor and Trend
  • Article Volume 2017 812
  • Article Volume 2016 714
  • Article Volume 2015 702
  • ISSN
  • 10780432
  • Open Access
  • Publisher
  • American Association for Cancer Research
  • Country/Region
  • United States
  • History
  • Categories
  • Cancer Research (Q1), Oncology (Q1)

Clinical Cancer Research - ISSN

The ISSN of Clinical Cancer Research is 10780432. An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

Clinical Cancer Research - ISSN

Clinical Cancer Research - Subscription (non-OA) Journal

Clinical Cancer Research is a Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles. Anyone who wants to use the articles in any way must obtain permission from the publishers.

Clinical Cancer Research - Open Access

Clinical Cancer Research - Publisher

Clinical Cancer Research is published by American Association for Cancer Research, which is located in the United States. The Publication History of Clinical Cancer Research covers 1995-ongoing.

Clinical Cancer Research - Publisher

Clinical Cancer Research - Categories

Clinical Cancer Research is a peer-reviewed scientific journal. The scope of Clinical Cancer Research covers Cancer Research (Q1), Oncology (Q1).

Clinical Cancer Research - Categories

Clinical Cancer Research - Journal Factors

It is impossible to get a true picture of impact using a single factor alone, so a basket of factors is needed to support informed decisions. In addition to Abbreviation, Acceptance Rate, Review Speed, Research Hotspot and Template, several advanced Journal Factors including Citescore, H-Index, Self-Citation Ratio, SJR (SCImago Journal Rank Indicator) and SNIP (Source Normalized Impact per Paper) can provide you comprehensive insights into the Clinical Cancer Research.

Clinical Cancer Research - Journal Metrics

Journal Ranking